For decades clinicians have been taught that pulmonary embolism-defined by the National Institutes of Health as a "sudden blockage in a lung artery" 1 -always matters and to be vigilant because a missed embolism can be fatal.
2 When a patient presents with shortness of breath, pleuritic chest pain, tachycardia, or signs of right heart strain, clinicians are trained to think "pulmonary embolism." Because these symptoms and signs are neither sensitive nor specific, scoring systems (such as the Wells criteria) have been developed to help clinicians decide which patients to scan, 3 although in practice, many clinicians simply proceed with imaging 4 to confirm or refute the diagnosis.
Explosion in use of CT imaging
Until recently, ventilation-perfusion (VQ) scanning, introduced in the mid-1960s, was the first line test for pulmonary embolism (table⇓) with clinicians maintaining an appropriately high threshold for invasive pulmonary angiography. 5 VQ scanning has the advantage of being non-invasive, but the results are often inconclusive. A new technology introduced in 1998-multidetector computed tomographic (CT) pulmonary angiography-offers higher resolution and more definitive results.
With the increasing availability of CT scanners, there has been an explosion in the use of CT for various indications, 6 including pulmonary embolism. A 2005 US survey of emergency department physicians showed that most considered CT pulmonary angiography to be the first line test for pulmonary embolism. 7 This finding is consistent with observations in health maintenance organisations 8 : use of CT pulmonary angiography rose 14-fold (from 0.3 to 4.0 per 1000 beneficiaries) while VQ scanning decreased by 52% (from 2.3 to 1.1 per 1000 beneficiaries) from 2001 to 2008.
Drivers for the increased use of CT pulmonary angiography
Clinicians like CT pulmonary angiography because it allows them to find causes besides pulmonary embolism to explain non-specific symptoms (such as pleural effusion or pneumonia). 7 But the main reason why doctors have embraced the technique is to avoid missing "a silent killer." 9 The widespread availability of CT pulmonary angiography has also encouraged doctors to lower their threshold for looking for pulmonary embolism. 10 With more testing, more pulmonary emboli are found. These extra diagnoses lead to testing even more patients because of the pervasive belief that finding even a tiny, subsegmental pulmonary embolism means you may have saved a life. Case finding has also increased as a result of the widespread use of non-specific blood tests like D-dimer and troponin, which raise suspicion of pulmonary embolism (and imaging to look for it) in patients in whom it would not otherwise have been considered. 11 Radiologists like CT pulmonary angiography because they can make definitive diagnoses more readily than with VQ scans. 12 Concerns about accusations of malpractice may also increase the use of CT pulmonary angiography. 13 Commercial interests are also fuelling imaging rates Purchasing the most advanced multidetector scanners can help a hospital establish a reputation for being on the cutting edge. To recoup the cost of the scanner, though, the machines must be used. 6 In addition, deep vein thrombosis and pulmonary embolism awareness campaigns led by drug companies have encouraged patients to ask about testing. In the US, Sanofi-Aventis, which produces the anticoagulant enoxaparin, ran the direct to consumer advertising campaign "killer legs," sponsored conferences on "economy class syndrome" (deep vein thrombosis and pulmonary embolism among air travellers); 14 and created a website featuring scary anecdotes like, "My husband didn't have to die," written by "people just like you" (Preventdvt.org). It also successfully lobbied the US Congress to declare an annual deep vein thrombosis awareness month and a national screening day.
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Evidence of overdiagnosis
The high resolution of CT pulmonary angiography makes it possible to detect filling defects in subsegmental arteries as small as 2-3 mm in diameter. 16 Only 1% of VQ scans rated as "high probability" correspond to an isolated subsegmental pulmonary embolism, 17 compared with 15% of positive CT pulmonary angiography scans. 18 If all pulmonary emboli caused important harm or death if untreated, finding more small clots would be an unqualified advance. However, there is evidence that some small clots do not need treatment, and finding them represents overdiagnosis. It has been argued that a normal function of the lungs is to act as a sieve to prevent small emboli formed in leg veins from travelling to the systemic arterial circulation with devastating effect, such as stroke. 19 These emboli are believed to be resorbed by the body without treatment and to have no clinical effect. This idea is supported by the finding that a surprisingly high proportion of consecutive contrast CT scans performed for other indications found incidental pulmonary emboli: in 16% of mechanically ventilated patients, 20 in 17% of inpatients over age 80, 21 and in 20% of trauma patients. 22 In addition, 50-60% of consecutive patients having autopsy were found to have an unsuspected pulmonary embolism when the pulmonary arteries were carefully dissected. 23 Natural course studies of subsegmental pulmonary embolism also provide evidence that some emboli may not need to be found. Donato and colleagues summarised three month outcomes of 192 patients with isolated subsegmental pulmonary embolism reported in the literature. 24 Among the 65 patients who did not receive anticoagulants (at the clinician's discretion), none had a recurrent pulmonary embolism or death. And only one of the 127 patients who received anticoagulation had a recurrent (non-fatal) pulmonary embolism, a substantially lower rate than the typical recurrence rate with larger pulmonary embolism (6%). 25 Evidence from population trends and one randomised trial also supports the view that pulmonary embolism is overdiagnosed. [26] [27] [28] [29] [30] Using national US administrative data, we showed that age adjusted incidence of pulmonary embolism, which was stable in the five years before the introduction of multidetector CT pulmonary angiography, increased by 80% in the eight years after it was introduced: from 62.1 to 112.3 per 100 000 US adults ( fig 1⇓) . 26 Despite this near doubling of diagnoses, age adjusted mortality from pulmonary embolism (deaths in the US population) changed little: from 12.3 to 11.9 per 100 000. Age adjusted case fatality of pulmonary embolism (in-hospital deaths), however, decreased by one third, from 12.1% to 7.8%, P<0.001), suggesting that the extra pulmonary emboli being detected are less lethal (given that treatment has not become more effective). More non-fatal pulmonary emboli dilute case fatality but do not change mortality. Similar patterns have been observed at the state level. 27 28 The rising incidence of pulmonary embolism and stable mortality is particularly striking given the simultaneous push for venous thromboembolism prophylaxis for hospital patients, most notably through the adoption of a national quality measure (http://qualitymeasures.ahrq.gov). More systematic use of prophylaxis would be expected to decrease both pulmonary embolism incidence and mortality. Nevertheless, incidence has risen. This rise is unlikely to represent a true change in the underlying rate of pulmonary embolism, as the major risk factors for pulmonary embolism have not shown a parallel increase. 27 The more likely explanation is increased use of CT in general 6 resulting in incidental detection of pulmonary embolism on contrast CT scans performed for other reasons [20] [21] [22] ) and CT pulmonary angiography specifically.
Limitations of the evidence
Inferring overdiagnosis by observing epidemiological trends has limitations because the evidence is derived from administrative data (coding on discharge records and death certificates) with imperfect accuracy, insufficient clinical detail, and lack of standardisation across institutions. But its strength lies in its representativeness of the population and reflection of actual clinical practice, in contrast with randomised trials that study a highly selected population under highly controlled conditions.
Case series that identified patients with pulmonary embolism by review of imaging for suspected embolism rather than relying
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe on discharge coding have been able to link outcomes to individual patients. These single institution series show that the rise in incidence is largely due to the increased detection of subsegmental pulmonary embolism. 31 32 33 The best evidence of overdiagnosis comes from a trial that randomised 1417 patients with an intermediate to high probability of pulmonary embolism to receive VQ scanning or CT pulmonary angiography. 30 Although CT pulmonary angiography detected more emboli than VQ scans (19.2% v 14.2%, P=0.01), there was no difference in death from pulmonary embolism or other unknown causes (0.3% v 0.3%) over three months.
Definitive evidence of overdiagnosis would, of course, be the finding that untreated patients never experienced harm from the pulmonary embolism during the rest of their lives and died from another cause, but no such studies exist.
Harms to patients and cost to health systems from overdiagnosis
The main harm from overdiagnosis is unnecessary treatment, which in the case of pulmonary embolism means anticoagulation-a leading cause of medication related death. 34 Because of ongoing controversy about duration of therapy, exposure to unnecessary and dangerous anticoagulation may be lifelong. In some studies, complications of anticoagulation are more common than the problem treatment is meant to prevent: recurrent venous thromboembolism. Notably, in the largest case series of patients given anticoagulants for isolated subsegmental pulmonary embolism (n=93), the risk of major bleeding was 5.3% but the risk of recurrent venous thromboembolism was only 0.7%. 24 In our study, in parallel with the increased incidence of pulmonary embolism, we found presumed anticoagulation complications for US patients admitted to hospital with pulmonary embolism to have increased from 3.1 to 5.3 per 100 000 (P<0.001) between 1998 and 2006. 26 Overdiagnosis also causes patients harm from inconvenience and anxiety. The current standard of care (warfarin) requires frequent blood tests, dietary changes, and constant fear of bleeding or clotting if the international normalised ratio is not in the target range. Patients may also be harmed by the fear and anxiety from being unnecessarily told that they have a potentially life threatening disease. 23 In addition, health insurers may charge them higher premiums because they have a "pre-existing condition."
Overdiagnosis and overtreatment are also costly to health systems. The mean charge associated with admission for pulmonary embolism in the US increased from roughly $25 000 (£17 000; €19 000) to $44 000 between 1998 and 2006. 35 The mean cost of subsequent warfarin anticoagulation, associated laboratory tests, and clinic visits was $2694. 36 The recent introduction of newer anticoagulants (dabigatran, rivaroxaban) will decrease the need for testing, but the drugs are substantially more expensive than warfarin ($3000 v $48 a year 37 ).
How to do better
Pulmonary embolism is underdiagnosed as well as overdiagnosed, 38 and ideally, improved tests would make it possible to find all clinically important emboli before patients experience an adverse outcome. Unfortunately, although highly sensitive tests find more emboli, they do so at the cost of overdiagnosis.
Addressing the problem of overdiagnosis is challenging (box).
The answer is not simply to do less testing-clinicians should continue to have a low threshold for considering pulmonary embolism-but to test (and subsequently treat) more selectively and to consider alternative tests such as VQ scanning and ultrasonography when appropriate.
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Take steps to image less
Clinical practice guidelines 11 40 41 and the Choosing Wisely Campaign 42 suggest clinicians should reserve CT pulmonary angiography for patients at intermediate to high risk of pulmonary embolism based on algorithms that combine clinical probability and D-dimer test results. 43 Large, prospective studies have shown the safety of this approach. 43 44 Use of algorithms could be increased by inserting them into the ordering process for CT pulmonary angiography 45 or empowering radiologists to challenge use of CT pulmonary angiography in patients with a low likelihood of pulmonary embolism. 12 Avoiding CT pulmonary angiography in patients with a low likelihood of pulmonary embolism would reduce exposure to nephrotoxic contrast and carcinogenic radiation. The average effective radiation dose from a CT pulmonary angiography is 10-15 millisieverts (compared with 2-2.5 mSV for a VQ scan and 5 mSV for invasive pulmonary angiography). 10 46 The radiation exposure is particularly worrisome for young women; for every 1000 20 year old women who have CT pulmonary angiography, about three will develop cancer. 10 Less CT pulmonary angiography would also mean fewer false positive results and "incidentalomas." Roughly a quarter of CT pulmonary angiographs detect an unexpected abnormality such as a pulmonary nodule, thyroid nodule, or adenopathy, resulting in further scans or invasive testing to rule out cancer. 47 Most are false alarms.
Consider less sensitive imaging
An alternative for clinically stable patients is to use other tests for venous thromboembolism, such as VQ scan or Doppler ultrasonography of the legs. Implementing policies to use VQ scans as the first line test for pulmonary embolism in stable patients with a normal x ray appearance can reduce use of CT pulmonary angiography and decrease detection of subsegmental pulmonary embolism without increasing deaths from pulmonary embolism. 29 48 Consider not treating some subsegmental pulmonary emboli Although some guidelines recommend anticoagulation for all pulmonary emboli, 41 49 others acknowledge that anticoagulation may not be warranted in all cases because of uncertainty about the balance of benefits and harms for treating isolated subsegmental pulmonary embolism. 11 40 Some authors suggest withholding anticoagulation for stable patients with isolated subsegmental pulmonary embolism and adequate cardiopulmonary reserve. 50 If a subsegmental pulmonary embolism is not treated, patients should be monitored for new respiratory symptoms and for deep vein thrombosis with serial ultrasonography for three to six months to decide whether anticoagulation can be safely withheld.
Unresolved questions
Many unresolved questions remain which require further research. What is the natural course and prognosis of untreated subsegmental pulmonary embolism? Does asymptomatic, incidentally detected pulmonary embolism have the same 
CT pulmonary angiography is always the best test
• CT pulmonary angiography is sensitive and easy to get, but for clinically stable patients, alternative tests reduce exposure radiation, cost less, and are less likely to lead to overdiagnosis
• VQ scans may make more sense for younger patients (less radiation), patients with normal lungs (a definitive result is more likely), and patients with renal dysfunction (no nephrotoxic contrast)
• Detection of deep vein thrombosis by ultrasonography of the legs when pulmonary embolism is suspected makes subsequent lung imaging unnecessary because patients need anticoagulation anyway
All patients need anticoagulants
• For patients with an isolated subsegmental pulmonary embolism harms may outweigh benefits. Patients with subsegmental emboli who take anticoagulants have a low chance of having another clot (0.7%) but a 5.3% chance of major bleeding 24
• Patients need to understand these trade-offs and be offered the opportunity to choose whether to take anticoagulants outcomes and prognosis as symptomatic pulmonary embolism? What are the benefits and harms of treating subsegmental pulmonary embolism with anticoagulation?
Conclusion
Pulmonary embolism is unquestionably an important cause of death, and rapid diagnosis and treatment can be life saving. But the diagnostic zeal and technological advances meant to improve outcomes of patients with pulmonary embolism are double edged swords: some patients are helped, but many are harmed through overdiagnosis and overtreatment. The idea that pulmonary embolism can be overdiagnosed will be new and counterintuitive for some clinicians, but the harms are just as real as those of underdiagnosis. To improve outcomes for all patients, we need to learn more about which small emboli need treatment. Importantly, an ongoing prospective cohort study is assessing the safety of withholding treatment for stable patients with isolated subsegmental pulmonary embolism (ClinicalTrials.gov Identifier: NCT01455818). 
